Associated Papers
Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations.
Fiskus W et al.
Blood Cancer Journal, 2025
40089460 (PubMed )
Supplement: 41408_2025_1251_MOESM2_ESM.pdf
Select a paper to view details